Low incidence of hypogonadism after radiation therapy for prostate cancer
Author Information
Author(s): Eric K Oermann, Simeng Suy, Heather N Hanscom, Joy S Kim, Sue Lei, Xia Yu, Guowei Zhang, Brook Ennis, JoyAnn P Rohan, Nathaniel Piel, Benjamin A Sherer, Devin Borum, Viola J Chen, Gerald P Batipps, Nicholas L Constantinople, Stephen W Dejter, Gaurav Bandi, John Pahira, Kevin G McGeagh, Lucile Adams-Campbell, Reena Jha, Nancy A Dawson, Brian T Collins, Anatoly Dritschilo, John H Lynch, Sean P Collins
Primary Institution: Georgetown University Hospital, Washington, D.C., USA
Hypothesis
Does hypofractionated stereotactic body radiation therapy (SBRT) lead to biochemical and clinical hypogonadism in prostate cancer patients?
Conclusion
Hypofractionated SBRT is well-tolerated and results in a low rate of new biochemical and clinical hypogonadism one year after treatment.
Supporting Evidence
- All patients completed treatment with a median follow-up of 15 months.
- Median pre-treatment PSA decreased from 5.75 ng/ml to 0.7 ng/ml by one year post-treatment.
- Post-treatment testosterone levels decreased in 69% of patients, but no new cases of biochemical hypogonadism were observed.
Takeaway
This study found that men with prostate cancer who received a specific type of radiation therapy had very few problems with hormone levels afterward.
Methodology
Twenty-six patients were treated with SBRT to a dose of 36.25 Gy in 5 fractions, with testosterone and PSA levels measured before and after treatment.
Potential Biases
Potential selection bias due to retrospective design.
Limitations
The study had a small sample size and short follow-up duration.
Participant Demographics
Median age was 69 years, with a mix of Caucasian and African American participants.
Statistical Information
P-Value
0.013
Confidence Interval
not provided
Statistical Significance
p<0.013
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website